Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

Impact · against what's priced in

Insilico Medicine (3696) sees a significant valuation catalyst as it validates its AI-driven discovery model with a Phase III trial and achieves its first profitable half-year. For Eli Lilly, the news is immaterial as these collaborations are a negligible fraction of the scale required to shift the needle on its GLP-1 centered valuation.

LLY+0.00: Doesn't touch the price's assumptions
The price assumes: Sustaining growth above 30% beyond 2026

Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

What matters in this story

iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity Pipeline

Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

What matters in this story

iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity Pipeline

How each ticker is affected

Connected tickers

Track these names every morning.

Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold

Beyond Air, Inc. (XAIR) Q2 2027 Earnings Call Transcript

Kodiak Sciences to Present at Three Upcoming Investor Conferences

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

What matters in this story

Next reads from the same story arc

iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity Pipeline

Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

What matters in this story

Next reads from the same story arc

iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity Pipeline

How each ticker is affected

Connected tickers

Track these names every morning.

Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold

Beyond Air, Inc. (XAIR) Q2 2027 Earnings Call Transcript

Kodiak Sciences to Present at Three Upcoming Investor Conferences

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development